Developments in therapies for AML - chemotherapy, targeted therapy and immunotherapy
Hagop M. Kantarjian
The importance of educating patients about adverse effects of treatment
Prognostic markers for CLL - how do they help determine who gets which treatment?
A new era in CLL
The influence of the European Research Initiative on CLL (ERIC)